Skip to main content

Table 1 Patient characteristics

From: A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study

Characteristic

Arm A: IRI+LV+5FU N = 441 (%)

Arm B: LV+5FU N = 432 (%)

P

Age (years)

  

0.336

   Median

65

65

 

   Range

26 to 79

24 to 79

 

Sex

  

0.892

   Female

206 (47)

199 (46)

 

   Male

235 (53)

233 (54)

 

Stage (Dukes)

  

0.946

   B

214 (48)

211 (49)

 

   C

227 (52)

221 (51)

 

Primary tumor (T)

  

0.891

   T1 and T2

29 (6)

27 (6)

 

   T3 and T4

405 (92)

399 (93)

 

   Unknown

7 (2)

6 (1)

 

Regional lymph nodes (N)

  

0.350

   N0

210 (48)

208 (48)

 

   N1

153 (35)

134 (31)

 

   N2

70 (16)

82 (19)

 

   Unknown

8 (2)

8 (2)

 

Histology grade

  

0.048

   I

40 (9)

47 (11)

 

   II

334 (76)

296 (68)

 

   III

62 (14)

84 (20)

 

   Unknown

5 (1)

5 (1)

 

Number of lymph nodes examined

  

0.354

   Median

14

14

 

   Range

0 to 96

0 to 70

 

Number of lymph nodes involved*

  

0.271

   Median

2

3

 

   Range

1 to 23

1 to 27

 

Site of disease

  

0.640

   Cecum

88 (20)

95 (22)

 

   Ascending colon

67 (15)

67 (16)

 

   Transverse colon

29 (7)

30 (7)

 

   Descending colon

36 (8)

44 (10)

 

   Sigmoid

218 (49)

194 (45)

 

   Unknown

4 (1)

2 (0.5)

 

Perforation

  

0.897

   Yes

406 (92)

398 (92)

 

   No

33 (7)

31 (7)

 

   Unknown

2 (1)

3 (1)

 

Obstruction

  

0.277

   Yes

386 (88)

365 (84)

 

   No

54 (12)

64 (15)

 

   Unknown

1 (0.2)

3 (1)

 

*Only for stage C disease

  Â